Search

Your search keyword '"Murphy, Declan"' showing total 219 results
Start Over Author "Murphy, Declan" Publisher elsevier b.v.
219 results on '"Murphy, Declan"'

1. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer

Author

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg, Hofman, Michael S., and Emmett, Louise

Published
2024
Full Text
View/download PDF

4. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study

Author

Eapen, Renu S., Buteau, James P., Jackson, Price, Mitchell, Catherine, Oon, Sheng F., Alghazo, Omar, McIntosh, Lachlan, Dhiantravan, Nattakorn, Scalzo, Mark J., O'Brien, Jonathan, Sandhu, Shahneen, Azad, Arun A., Williams, Scott G., Sharma, Gaurav, Haskali, Mohammad B., Bressel, Mathias, Chen, Kenneth, Jenjitranant, Pocharapong, McVey, Aoife, Moon, Daniel, Lawrentschuk, Nathan, Neeson, Paul J., Murphy, Declan G., and Hofman, Michael S.

Published
2024
Full Text
View/download PDF

5. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology

Author

Eppler, Michael, Ganjavi, Conner, Ramacciotti, Lorenzo Storino, Piazza, Pietro, Rodler, Severin, Checcucci, Enrico, Gomez Rivas, Juan, Kowalewski, Karl F., Belenchón, Ines Rivero, Puliatti, Stefano, Taratkin, Mark, Veccia, Alessandro, Baekelandt, Loïc, Teoh, Jeremy Y.-C., Somani, Bhaskar K., Wroclawski, Marcelo, Abreu, Andre, Porpiglia, Francesco, Gill, Inderbir S., Murphy, Declan G., Canes, David, and Cacciamani, Giovanni E.

Published
2024
Full Text
View/download PDF

6. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature

Author

Sood, Akshay, Kishan, Amar U., Evans, Christopher P., Feng, Felix Y., Morgan, Todd M., Murphy, Declan G., Padhani, Anwar R., Pinto, Peter, Van der Poel, Henk G., Tilki, Derya, Briganti, Alberto, and Abdollah, Firas

Published
2024
Full Text
View/download PDF

7. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy

Author

Kelly, Brian D., Ptasznik, Gideon, Roberts, Matthew J., Doan, Paul, Stricker, Phillip, Thompson, James, Buteau, James, Chen, Kenneth, Alghazo, Omar, O'Brien, Jonathan S., Hofman, Michael S., Frydenberg, Mark, Lawrentschuk, Nathan, Lundon, Dara, Murphy, Declan G., Emmett, Louise, and Moon, Daniel

Published
2023
Full Text
View/download PDF

8. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis

Author

Chow, Kit Mun, So, Wei Zheng, Lee, Han Jie, Lee, Alvin, Yap, Dominic Wei Ting, Takwoingi, Yemisi, Tay, Kae Jack, Tuan, Jeffrey, Thang, Sue Ping, Lam, Winnie, Yuen, John, Lawrentschuk, Nathan, Hofman, Michael S., Murphy, Declan G., and Chen, Kenneth

Published
2023
Full Text
View/download PDF

12. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Castellano, Daniel, Castro, Elena, Cheng, Heather H., Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ngozi Ekeke, Onyeanunam, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fonteyne, Valerie, Fossati, Nicola, Frydenberg, Mark, George, Daniel, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara Alicja, Jones, Robert, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Kramer, Gero, Leibowitz, Raya, Logothetis, Christopher J., Mahal, Brandon A., Maluf, Fernando, Mateo, Joaquin, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark. A., Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver A., Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Turco, Fabio, Uemura, Hiroji, Uemura, Hirotsugu, Ürün, Yüksel, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, and Omlin, Aurelius

Published
2023
Full Text
View/download PDF

16. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

Author

Fanti, Stefano, Briganti, Alberto, Emmett, Louise, Fizazi, Karim, Gillessen, Silke, Goffin, Karolien, Hadaschik, Boris A., Herrmann, Ken, Kunikowska, Jolanta, Maurer, Tobias, MacLennan, Steven, Mottet, Nicolas, Murphy, Declan G., Oprea-Lager, Daniela E., O'Sullivan, Joe M., Oyen, Wim J.G., Rouvière, Olivier, Sartor, Oliver, Stenzl, Arnulf, Van Poppel, Hendrik, Walz, Jochen, Witjes, Wim, and Bjartell, Anders

Published
2022
Full Text
View/download PDF

18. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature

Author

Manfredi, Celeste, Fernández-Pascual, Esaú, Arcaniolo, Davide, Emberton, Mark, Sanchez-Salas, Rafael, Artigas Guix, Carlos, Bianco, Fernando, Cathcart, Paul, Murphy, Declan G., Couñago, Felipe, Martínez-Ballesteros, Claudio, Verze, Paolo, and Martínez-Salamanca, Juan Ignacio

Published
2022
Full Text
View/download PDF

19. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline S., Clarke, Noel, Davis, Ian D., de Bono, Johann S., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S., Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Rob E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan P., Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E., Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

20. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial

Author

Siva, Shankar, Bressel, Mathias, Wood, Simon T., Shaw, Mark G., Loi, Sherene, Sandhu, Shahneen K., Tran, Ben, A. Azad, Arun, Lewin, Jeremy H., Cuff, Katharine E., Liu, Howard Y., Moon, Daniel, Goad, Jeremy, Wong, Lih-Ming, LimJoon, Michael, Mooi, Jennifer, Chander, Sarat, Murphy, Declan G., Lawrentschuk, Nathan, and Pryor, David

Published
2022
Full Text
View/download PDF

28. Report of the third Asian Prostate Cancer study meeting

Author

Lojanapiwat, Bannakij, Lee, Ji Youl, Gang, Zhu, Kim, Choung-Soo, Fai, Ng Chi, Hakim, Lukman, Umbas, Rainy, Ong, Teng Aik, Lim, Jasmine, Letran, Jason L., Chiong, Edmund, Lee, Seung Hwan, Türkeri, Levent, Murphy, Declan G., Moretti, Kim, Cooperberg, Matthew, Carlile, Robert, Hinotsu, Shiro, Hirao, Yoshihiko, Kitamura, Tadaichi, Horie, Shigeo, Onozawa, Mizuki, Kitagawa, Yasuhide, Namiki, Mikio, Fukagai, Takashi, Miyazaki, Jun, and Akaza, Hideyuki

Published
2019
Full Text
View/download PDF

29. Role of FDG PET/CT in Management of Patients with Prostate Cancer.

Author

Sutherland, Duncan E.K., Azad, Arun A., Murphy, Declan G., Eapen, Renu S., Kostos, Louise, and Hofman, Michael S.

Abstract

Prostate cancer is the second most common cancer in men worldwide. [18F]FDG PET/CT imaging, a well-known and effective technique for detecting malignancies, has not been considered a useful tool for prostate cancer imaging by many because of its perceived low [18F]FDG uptake. Incidentally detected focal [18F]FDG uptake in the prostate is not uncommon, and typically benign. Imaging features that would increase concern for an underlying prostatic carcinoma, include focal uptake in the periphery near the gland margin without calcifications. [18F]FDG PET/CT imaging provides little value in the initial staging of prostate cancer, particularly in the era of prostate specific membrane antigen (PSMA) radiotracer. In cases of biochemical recurrence, the value of [18F]FDG PET/CT increases notably when Grade group 4 or 5 and elevated PSA levels are present. Active research is underway for theranostic approaches to prostate cancer, including [177Lu]Lu-PSMA therapy. Dual tracer staging using FDG and PSMA imaging significantly enhances the accuracy of disease site assessment. Specifically, the addition of [18F]FDG PET/CT imaging allows for the evaluation of discordant disease (PSMA negative/FDG positive). The maximal benefit from [177Lu]Lu-PSMA therapy relies on significant PSMA accumulation across all disease sites, and the identification of discordant disease suggests that these patients may derive less benefit from the treatment. The genuine value of [18F]FDG PET/CT imaging lies in advanced prostate cancer, PSMA-negative disease, as a prognostic biomarker, and the realm of new targeted theranostic agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting

Author

Kim, Choung-Soo, Lee, Ji Youl, Chung, Byung Ha, Kim, Wun-Jae, Fai, Ng Chi, Hakim, Lukman, Umbas, Rainy, Ong, Teng Aik, Lim, Jasmine, Letran, Jason L., Chiong, Edmund, Wu, Tong-lin, Lojanapiwat, Bannakij, Türkeri, Levent, Murphy, Declan G., Gardiner, Robert A., Moretti, Kim, Cooperberg, Matthew, Carroll, Peter, Mun, Seong Ki, Hinotsu, Shiro, Hirao, Yoshihiko, Ozono, Seiichiro, Horie, Shigeo, Onozawa, Mizuki, Kitagawa, Yasuhide, Kitamura, Tadaichi, Namiki, Mikio, and Akaza, Hideyuki

Published
2017
Full Text
View/download PDF

33. Asia prostate cancer study (A-CaP Study) launch symposium

Author

Akaza, Hideyuki, Hirao, Yoshihiko, Kim, Choung-Soo, Oya, Mototsugu, Ozono, Seiichiro, Ye, Dingwei, Cooperberg, Matthew, Hinotsu, Shiro, Lee, Ji Youl, Zhu, Gang, Namiki, Mikio, Horie, Shigeo, Chung, Byung Ha, Chen, Chung-Hsin, Fai, Ng Chi, Hakim, Lukman, Chiong, Edmund, Letran, Jason, Umbas, Rainy, Suzuki, Kazuhiro, Nishimura, Kazuo, Ong, Teng Aik, Lojanapiwat, Bannakij, Wu, Tong-lin, Kim, Wun-Jae, Murphy, Declan, Ogawa, Osamu, Carroll, Peter, Naito, Seiji, and Tsukamoto, Taiji

Published
2016
Full Text
View/download PDF

39. The Effect of Macular Hole Duration on Surgical Outcomes: An Individual Participant Data Study of Randomized Controlled Trials.

Author

Murphy, Declan C., Al-Zubaidy, Mo, Lois, Noemi, Scott, Neil, and Steel, David H.

Subjects
*RANDOMIZED controlled trials, *VITRECTOMY, *CHEMICAL peel, *BIBLIOGRAPHIC databases, *VISUAL acuity, *DIABETIC retinopathy, *PEOPLE with visual disabilities
Abstract

To define the effect of symptom duration on outcomes in people undergoing surgery for idiopathic full-thickness macular holes (iFTMHs) by means of an individual participant data (IPD) study of randomized controlled trials (RCTs). The outcomes assessed were primary iFTMH closure and postoperative best-corrected visual acuity (BCVA). Idiopathic full-thickness macular holes are visually disabling with a prevalence of up to 0.5%. Untreated BCVA is typically reduced to 20/200. Surgery can close holes and improve vision. Symptom duration is thought to affect outcomes with surgery, but the effect is unclear. A systematic review identified eligible RCTs that included adults with iFTMH undergoing vitrectomy with gas tamponade in which symptom duration, primary iFTMH closure, and postoperative BCVA were recorded. Bibliographic databases were searched for articles published between 2000 and 2020. Individual participant data were requested from eligible studies. Twenty eligible RCTs were identified. Data were requested from all studies and obtained from 12, representing 940 eyes in total. Median symptom duration was 6 months (interquartile range, 3–10). Primary closure was achieved in 81.5% of eyes. There was a linear relationship between predicted probability of closure and symptom duration. Multilevel logistic regression showed each additional month of duration was associated with 0.965 times lower odds of closure (95% confidence interval [CI], 0.935–0.996, P = 0.026). Internal limiting membrane (ILM) peeling, ILM flap use, better preoperative BCVA, face-down positioning, and smaller iFTMH size were associated with increased odds of primary closure. Median postoperative BCVA in eyes achieving primary closure was 0.48 logarithm of the minimum angle of resolution (logMAR) (20/60). Multilevel logistic regression showed for eyes achieving primary iFTMH closure, each additional month of symptom duration was associated with worsening BCVA by 0.008 logMAR units (95% CI, 0.005–0.011, P < 0.001) (i.e., ∼1 Early Treatment Diabetic Retinopathy Study letter loss per 2 months). ILM flaps, intraocular tamponade using long-acting gas, better preoperative BCVA, smaller iFTMH size, and phakic status were also associated with improved postoperative BCVA. Symptom duration was independently associated with both anatomic and visual outcomes in persons undergoing surgery for iFTMH. Time to surgery should be minimized and care pathways designed to enable this. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Modern Active Surveillance in Prostate Cancer: A Narrative Review.

Author

Pattenden, Trent A., Samaranayke, Dhanika, Morton, Andrew, Wee Loon Ong, Murphy, Declan G., Pritchard, Elizabeth, Evans, Susan, Millar, Jeremy, Chalasani, Venu, Rashid, Prem, Winter, Matthew, Vela, Ian, Pryor, David, Mark, Stephen, Lawrentschuk, Nathan, and Thangasamy, Isaac A.

Subjects
PROSTATE cancer treatment, WATCHFUL waiting, PROSTATE cancer risk factors, PATIENT selection, MEDICAL care
Abstract

The authors reviewed and sumarised the literature about active surveillance in prostate cancer. It provides a useful reference on patient selection criteria, surveillence investigations, barriers and enablers of active surveillence and evolving technologies that will be used in the future. The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection cr iter ia and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection cr iter ia recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Turco, Fabio, Armstrong, Andrew, Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G., Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Clarke, Caroline, Clarke, Noel, Davis, Ian D., de Bono, Johann, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Efstathiou, Jason, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celestia, Hofman, Michael S., Hussain, Maha, James, Nicholas, Jones, Rob, Kanesvaran, Ravindran, Khauli, Raja B., Klotz, Laurence, Leibowitz, Raya, Logothetis, Christopher, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ekeke Onyeanunam, Ngozi, Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Christopher, Poon, Darren M.C., Pritchard, Colin C., Rabah, Danny M., Rathkopf, Dana, Reiter, Robert E., Rubin, Mark, Ryan, Charles J., Saad, Fred, Pablo Sade, Juan, Sartor, Oliver, Scher, Howard I., Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel, Sternberg, Cora N., Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Gillessen, Silke, and Omlin, Aurelius

Published
2022
Full Text
View/download PDF

42. Corrigendum to “Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis” [Eur. Urol. 84(1) (2023) 36–48]

Author

Mun Chow, Kit, Zheng So, Wei, Jie Lee, Han, Lee, Alvin, Wei Ting Yap, Dominic, Takwoingi, Yemisi, Jack Tay, Kae, Tuan, Jeffrey, Ping Thang, Sue, Lam, Winnie, Yuen, John, Lawrentschuk, Nathan, Hofman, Michael S., Murphy, Declan G., and Chen, Kenneth

Published
2024
Full Text
View/download PDF

48. Inferior gluteal artery perforator (IGAP) flap versus profunda artery perforator (PAP) flap as an alternative option for free autologous breast reconstruction.

Author

Murphy, Declan C., Razzano, Sergio, Wade, Ryckie G., Haywood, Richard M., and Figus, Andrea

Abstract

When patients are unsuitable for deep inferior epigastric perforator (DIEP) flap breast reconstruction, the inferior gluteal artery perforator (IGAP) flap has been used as an alternative option. However, the profunda artery perforator (PAP) flap is also gaining popularity as an alternative to the DIEP flap for several reasons. This retrospective cohort study compares baseline characteristics, peri- and post-operative outcomes following IGAP flap and PAP flap breast reconstructions after mastectomy for cancer. In a single center in the UK, from September 2008 through December 2016, 43 women underwent IGAP Flap(s) breast reconstruction and 51 received PAP flap(s) breast reconstructions. Statistical analysis was performed to compare baseline, peri-operative and post-operative variables between the two reconstruction methods. Perioperative complications requiring reoperation were experienced in women undergoing IGAP flap breast reconstructions only (21% versus 0%, p = 0.001), principally due to the risk of total flap failure (12% versus 0%, p = 0.01). Women undergoing IGAP flap breast reconstructions were at significantly higher odds of revision surgery (OR 17 [95% CI: 5.5-53], p < 0.001), which was unchanged after adjusting for bilateral reconstructions (adjusted OR 18 [95% CI: 5.3-58], p < 0.001). PAP flaps appear to be associated with significantly fewer complications and revision surgeries than IGAP flaps for breast reconstruction in women undergoing mastectomy for cancer and who are unsuitable for a DIEP flap breast reconstruction. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Author

Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G., Chi, Kim N., Clarke, Noel, Davis, Ian D., de Bono, Johann, Drake, Charles G., Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia (Tia) S., Hofman, Michael S., Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B., Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K., Morris, Michael J., Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G., Murthy, Vedang, Oh, William K., Ost, Piet, O'Sullivan, Joe M., Padhani, Anwar R., Parker, Chris, Poon, Darren M.C., Pritchard, Colin C., Reiter, Robert E., Roach, Mack, Rubin, Mark, Ryan, Charles J., Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R., Taplin, Mary Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, Omlin, Aurelius, Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., Davis, I. D., de Bono, J., Drake, C. G., Duran, I., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. Y., Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Heinrich, D., Higano, C. T. S., Hofman, M. S., Hussain, M., James, N., Kanesvaran, R., Kantoff, P., Khauli, R. B., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A. K., Morris, M. J., Mottet, N., Mrabti, H., Murphy, D. G., Murthy, V., Oh, W. K., Ost, P., O'Sullivan, J. M., Padhani, A. R., Parker, C., Poon, D. M. C., Pritchard, C. C., Reiter, R. E., Roach, M., Rubin, M., Ryan, C. J., Saad, F., Sade, J. P., Sartor, O., Scher, H. I., Shore, N., Small, E., Smith, M., Soule, H., Sternberg, C. N., Steuber, T., Suzuki, H., Sweeney, C., Sydes, M. R., Taplin, M. -E., Tombal, B., Turkeri, L., van Oort, I., Zapatero, A., and Omlin, A.

Subjects
Tumour genomic profiling, Manchester Cancer Research Centre, Advanced prostate cancer, ResearchInstitutes_Networks_Beacons/mcrc, Progression-free survival, Hormone-sensitive prostate cancer, Oligometastatic prostate cancer, Imaging, High-risk localised prostate cancer, Prostate cancer treatment, Castration-naïve prostate cancer, Genetics, Overall survival, Castration-resistant prostate cancer
Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. Objective: To present the results from the APCCC 2019. Design, setting, and participants: Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. Results and limitations: Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results